Home › NDC Lookup › RxCUI directory › RxCUI 905390

Carglumic acid 200 MG Tablet for Oral Suspension — RxCUI 905390

RxNorm drug concept · Semantic clinical drug
RxCUI 905390 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI905390
Official nameCarglumic acid 200 MG Tablet for Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known ascarglumic acid 200 MG Dispersible Tablet for Oral Suspension
FDA products mapped4
Package NDCs mapped6
Reported Medicaid activity (SDUD)315 prescriptions · 5 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Carglumic acid 200 MG Tablet for Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Carglumic acid 200 MG Tablet for Oral Suspension RxCUI 905390

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Carglumic acid 401713
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Carbaglu 905391
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Carglumic acid Tablet for Oral Suspension 1869526
    • Carglumic acid Oral Liquid Product 1151394
    • Carglumic acid Oral Product 1151395
    • Carglumic acid Tablet for Oral Suspension [Carbaglu] 1869529
    • Carbaglu Oral Liquid Product 1173689
    • Carbaglu Oral Product 1173690
    • Tablet for Oral Suspension 1861409
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Carglumic acid 200 MG SCDC · 1869525
  • Carglumic acid Tablet for Oral Suspension SCDF · 1869526
  • Carglumic acid Oral Liquid Product SCDG · 1151394
  • Carglumic acid Oral Product SCDG · 1151395

Brand-Name Concepts

  • Carglumic acid 200 MG Tablet for Oral Suspension [Carbaglu] SBD · 905394
  • Carglumic acid 200 MG [Carbaglu] SBDC · 1869528
  • Carglumic acid Tablet for Oral Suspension [Carbaglu] SBDF · 1869529
  • Carbaglu Oral Liquid Product SBDG · 1173689
  • Carbaglu Oral Product SBDG · 1173690
  • Carbaglu BN · 905391

📦 FDA Products & Package NDCs

4 products · 6 package NDCs
6 package NDCs map to RxCUI 905390 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
35573-0459-60 60 TABLET, FOR SUSPENSION in 1 BOTTLE (35573-459-60) Carglumic acid Burel Pharmaceuticals, LLC 2022-12-19
52276-0312-05 5 TABLET, FOR SUSPENSION in 1 BOTTLE (52276-312-05) Carbaglu Recordati Rare Diseases 2010-03-18
52276-0312-60 60 TABLET, FOR SUSPENSION in 1 BOTTLE (52276-312-60) Carbaglu Recordati Rare Diseases 2010-03-18
68475-0006-01 5 TABLET, FOR SUSPENSION in 1 BOTTLE (68475-006-01) Carglumic acid Navinta LLC 2022-08-01
68475-0006-02 60 TABLET, FOR SUSPENSION in 1 BOTTLE (68475-006-02) Carglumic acid Navinta LLC 2022-08-01
71863-0114-60 1 BOTTLE in 1 CARTON (71863-114-60) / 60 TABLET, FOR SUSPEN... Carglumic Acid Eton Pharmaceuticals, Inc. 2021-12-20
Observed labelers: Navinta LLC (2) · Recordati Rare Diseases (2) · Burel Pharmaceuticals, LLC (1) · Eton Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.